| abstract |
ABSTRACT - 598294 The disclosure relates to heterocyclic compounds of structural formula (I) e.g. 2-phenyl-3-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)quinoxaline-6-carboxylic or a pharmaceutically acceptable salt or ester thereof which inhibit PAS Kinase (PASK) activity, wherein the variable are defined in the specification. Also disclosed are compositions comprising these heterocyclic compounds of formula (I) and their application as pharmaceuticals for the treatment of cancer and a metabolic disease is chosen from metabolic syndrome, diabetes mellitus, dyslipidemia, fatty liver disease, non-alcoholic steatohepatitis, obesity, and insulin resistance. |